Enhanced Cancer Therapy Using an Engineered Designer Cytokine Alone and in Combination With an Immune Checkpoint Inhibitor.

导出 LinkOut

翻译打印收藏纠错

第一作者： Anjan K,Pradhan

第一单位： Department of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, VA, United States.

作者： Anjan K,Pradhan ^[1] ; Praveen,Bhoopathi ^[2] ; Santanu,Maji ^[3] ; Amit,Kumar ^[1] ; Chunqing,Guo ^[2] ; Padmanabhan,Mannangatti ^[3] ; Jiong,Li ^[1] ; Xiang-Yang,Wang ^[2] ; Devanand,Sarkar ^[1] ; Luni,Emdad ^[2] ; Swadesh K,Das ^[1] ; Paul B,Fisher ^[2]

作者单位： Department of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, VA, United States. ^[1] Virginia Commonwealth University (VCU) Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, VA, United States. ^[2] Virginia Commonwealth University (VCU) Massey Cancer Center, Virginia Commonwealth University, School of Medicine, Richmond, VA, United States. ^[3] Department of Medicinal Chemistry, Philips Institute for Oral Health Research, Virginia Commonwealth University, School of Pharmacy, Richmond, VA, United States. ^[4]

关键词 M7S (IL-24S)insulin signal peptide; PD-L1 mda-7 (IL-24)melanoma secretory motif

DOI 10.3389/fonc.2022.812560

PMID 35402258

发布时间 2023-02-02

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in oncology

2022年12卷

812560页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Enhanced Cancer Therapy Using an Engineered Designer Cytokine Alone and in Combination With an Immune Checkpoint Inhibitor.

Frontiers in oncology

相似文献

Frontiers in oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Enhanced Cancer Therapy Using an Engineered Designer Cytokine Alone and in Combination With an Immune Checkpoint Inhibitor.

Frontiers in oncology

相似文献

Frontiers in oncology

相关期刊

检索历史清除